Create an Account

Genetics

Episodes 1-6 of 6

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial
    Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial

    Learn More

    Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial
    UP NEXT...
    The HPV Data Is In — What Do the Newest Updates in Screening Mean For Your Patients?

    Welcome to the new
    Global Oncology Academy website.

    NEW FEATURES:

    • Check out all the new educational programs we have added.New educational programs
    • Now mobile-friendly and easier to navigate.Now mobile-friendly
    • A learner profile that stores your history/CME certificates.Track your credits
    Register

    We’re glad to see you’re enjoying Global Oncology Academy…
    but how about a more personalized experience?

    Register for free
    You are now leaving Global Oncology Academy and going to a site run by another organization.

    Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.